The description of the multiple modes of action of the anti-HER3 antibody 9F7-F11 not only adds to our basic understanding of dysregulated signaling in cancer, but might help the selection of drug combinations and clinical indications for 9F7-F11 in NRG1-addicted or NRG1-rearranged cancer. Here, NRG1 is linked to cancer.